Lung cancer drug matching: lab test could personalize treatment

NCT ID NCT07636252

Recruiting now Knowledge-focused Sponsor: Sheba Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether testing lung cancer cells in a lab can predict which drugs will work best for each patient. Researchers will collect fluid from around the lungs of 400 people with lung cancer who need drainage for shortness of breath. They will grow the cancer cells in the lab and test different drugs to see if the results match the patient's genetic mutations and actual treatment response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors choose the most effective drugs for lung cancer patients based on lab tests, leading to more personalized treatment.
What could go wrong: This is an early observational study, not a treatment trial. The lab tests may not accurately predict real patient outcomes, and results may not apply to all lung cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma of Lung lung adenocarcinoma lung neoplasm myeloproliferative disorder, chronic, with eosinophilia Pleural Effusion, Malignant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG ADENOCARCINOMA MALIGNANT PLEURAL EFFUSIONS (MPE)

Contacts and locations

Locations

Sheba Medical Center
RECRUITING

Ramat Gan, Israel, 5262100, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.